Christina Cotte, MD
she/her/hers
DownloadHi-Res Photo
Cards
Contact Info
About
Titles
Hospital Resident
Education & Training
- Traditional Internal Medicine Resident
- Yale New Haven Hospital (2023)
- MD
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell (2023)
- BS (Hon)
- University of Connecticut, Molecular and Cell Biology; Pathobiology (2017)
Research
Research at a Glance
Publications Timeline
A big-picture view of Christina Cotte's research output by year.
5Publications
163Citations
Publications
2022
Plasma cell leukemia: Retrospective review of cases at Monter Cancer Center/Northwell Health Cancer Institute, 2014-2019
Cotte C, Hartley-Brown M. Plasma cell leukemia: Retrospective review of cases at Monter Cancer Center/Northwell Health Cancer Institute, 2014-2019. Current Problems In Cancer 2022, 46: 100831. PMID: 35091270, DOI: 10.1016/j.currproblcancer.2021.100831.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPlasma cell leukemiaNew agentsOverall survivalMultiple myelomaTreatment regimensNovel therapiesCases of PCLTri-specific antibodiesOptimal therapeutic approachProspective clinical trialsDifferent treatment regimensSpecific treatment regimensFulminant coursePrognostic factorsRetrospective reviewImmunomodulatory drugsRetrospective studyAggressive malignancyCancer CenterDisease characteristicsTreatment advancesClinical trialsCell leukemiaTherapeutic approachesDiagnostic criteria
2021
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
Giannis D, Allen S, Tsang J, Flint S, Pinhasov T, Williams S, Tan G, Thakur R, Leung C, Snyder M, Bhatia C, Garrett D, Cotte C, Isaacs S, Gugerty E, Davidson A, Marder G, Schnitzer A, Goldberg B, McGinn T, Davidson K, Barish M, Qiu M, Zhang M, Goldin M, Matsagkas M, Arnaoutoglou E, Spyropoulos A, Consortium O. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood 2021, 137: 2838-2847. PMID: 33824972, PMCID: PMC8032474, DOI: 10.1182/blood.2020010529.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIntensive care unitArterial thromboembolismVenous thromboembolismMajor bleedingPostdischarge anticoagulationPostdischarge thromboprophylaxisVTE scorePrimary outcomeAdvanced ageCoronavirus disease 2019 (COVID-19) inpatientsPostdischarge venous thromboembolismPrincipal safety outcomePrior venous thromboembolismCardiovascular risk factorsChronic kidney diseasePeripheral arterial diseasePrimary outcome rateCarotid occlusive diseaseCoronary artery diseaseCOVID-19 hospitalizationCOVID-19Electronic health recordsThromboembolic outcomesVTE ratesCause mortality
2017
Peritoneal B-1b and B-2 B-cells confer long-term protection from pneumococcal serotype 3 infection after vaccination with Prevnar-13 and are defective in sickle cell disease mice
Cotte C, Szczepanek S. Peritoneal B-1b and B-2 B-cells confer long-term protection from pneumococcal serotype 3 infection after vaccination with Prevnar-13 and are defective in sickle cell disease mice. Vaccine 2017, 35: 3520-3522. PMID: 28545925, DOI: 10.1016/j.vaccine.2017.05.039.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsLong-term immunitySickle cell disease micePrevnar-13SCD miceDisease miceRecipient miceB cellsPneumococcal conjugate vaccineMice three timesB cell subsetsWild-type miceB-1aB-1a cellsSerotype 3 infectionB-1bConjugate vaccineWT miceLong-term protectionStreptococcus pneumoniaeSubset functionsMiceVaccinationWeek intervalsImmunityThree times
2016
Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers
Szczepanek S, Roberts S, Rogers K, Cotte C, Adami A, Bracken S, Salmon S, Secor E, Thrall R, Andemariam B, Metzger D. Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers. PLOS ONE 2016, 11: e0149261. PMID: 26910228, PMCID: PMC4766082, DOI: 10.1371/journal.pone.0149261.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSickle cell diseaseAnti-pneumococcal antibody titerSCD miceAntibody titersPrevnar-13Pneumococcal vaccinationPneumococcal infectionControl miceSickle cell disease miceIntranasal pneumococcal infectionPoor long-term efficacyLong-term efficacyMouse challenge modelPolysaccharide conjugate vaccinesInitial IgGPneumococcal vaccineIntranasal infectionIgM responseAntibody responseDisease miceImmune protectionPneumococcal polysaccharideSCD groupCell diseaseCommon cause- 0000-0002-8385-1921Peer-Reviewed Original Research